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Abstract
Background: Caudal regression syndrome (CRS) or sacral agenesis is a rare congenital disorder characterized by a
constellation of congenital caudal anomalies affecting the caudal spine and spinal cord, the hindgut, the urogenital
system, and the lower limbs. CRS is a complex condition, attributed to an abnormal development of the caudal
mesoderm, likely caused by the effect of interacting genetic and environmental factors. A well-known risk factor is
maternal type 1 diabetes.
Method: Whole exome sequencing and copy number variation (CNV) analyses were conducted on 4 Caucasian
trios to identify de novo and inherited rare mutations.
Results: In this pilot study, exome sequencing and copy number variation (CNV) analyses implicate a number of
candidate genes, including SPTBN5, MORN1, ZNF330, CLTCL1 and PDZD2. De novo mutations were found in SPTBN5,
MORN1 and ZNF330 and inherited predicted damaging mutations in PDZD2 (homozygous) and CLTCL1 (compound
heterozygous). Importantly, predicted damaging mutations in PTEN (heterozygous), in its direct regulator GLTSCR2
(compound heterozygous) and in VANGL1 (heterozygous) were identified. These genes had previously been linked
with the CRS phenotype.
Two CNV deletions, one de novo (chr3q13.13) and one homozygous (chr8p23.2), were detected in one of our CRS
patients. These deletions overlapped with CNVs previously reported in patients with similar phenotype.
Conclusion: Despite the genetic diversity and the complexity of the phenotype, this pilot study identified genetic
features common across CRS patients.
Keywords: Sacral agenesis, Caudal regression, Copy-number variation, Whole exome sequencing
Background
Caudal Regression Syndrome (CRS; Caudal Dysgenesis
Syndrome, Caudal Dysplasia Sequence, Congenital
Sacral Agenesis; OMIM 600145) is a rare (1 in 7,500–
100,000 births [1, 2]) congenital disorder characterized
by varying degrees of spinal column agenesis. Associated
with it are anomalies of central nervous, genito-urinary,
cardiac, respiratory and gastro-intestinal systems [3]
with anorectal malformations (ARMs) being the most
common.
CRS has been attributed to abnormal fetal develop-
ment of the caudal mesoderm before the fourth week of
gestation [4]. During the abnormal gastrulation, pro-
spective notochordal cells, that are wrongly specified in
terms of their rostrocaudal positional encoding, are
eliminated. Eventually, fewer or even no cells will be
available to form the notochord at a given abnormal seg-
mental level. The consequences of such segmental noto-
chordal paucity are manifold and affect the development
of the spinal column and spinal cord as well as other
organs that rely on the notochord as their inductor. If
the prospective notochord is depleted a wide array of
segmental vertebral malformations may develop
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including segmentation defects, indeterminate or block
vertebrae, or absence of several vertebrae. Because of
lack of neural induction and absence of a floor plate,
fewer prospective neuroectodermal cells will be induced
to form the neural tube. The resulting malformation es-
sentially depends on the segmental level and the extent
of the abnormality along the longitudinal embryonic
axis, with subsequent interference on the processes of
primary and/or secondary neurulation [5]. However,
what triggers such abnormal events is not known.
Caudal spinal abnormalities are the defining character-
istics of CRS. Cama et al. [6] and Pang et al. [7] classified
the disorder into 5 categories according to the degree of
caudal spine involvement: Type I) total sacral agenesis
with normal or short transverse pelvic diameter and
some lumbar vertebrae possibly missing; Type II) total
sacral agenesis without involvement of lumbar vertebrae;
Type III) subtotal sacral agenesis or sacral hypodevelop-
ment; Type IV hemisacrum and Type V) coccygeal
agenesis.
Maternal type 1 diabetes is a risk factor for CRS, as it
is for many other congenital disorders [8]. Maternal type
1 diabetes confers a higher relative risk (252) for CRS
than for any congenital diosorder [9]. The exact mech-
anism by which maternal diabetes affects fetal develop-
ment in humans remains unclear [10]. While animal
studies have shown that embryos exposed to higher
levels of glucose develop growth anomalies, hypergly-
cemia has not been associated with abnormal fetal devel-
opment in humans [11]. During normal pregnancies
insulin sensitivity is reduced at the start of the third tri-
mester in order to provide metabolic fuel for both
mother and the developing fetus. However, since insulin
is unable to cross the placenta, the fetus starts producing
its own insulin in order to metabolize nutrition. It has
been suggested that insulin, antibodies to insulin, or
some other abnormality of carbohydrate metabolism
could affect the development of a genetically susceptible
fetus [12, 13].
Evidence for a genetic cause is provided by the exist-
ence of familial segregation as well as animal models.
While the most severe forms of CRS present sporadic-
ally, milder CRS forms can be transmitted within fam-
ilies in a dominant manner with reduced penetrance and
phenotypic variability [4]. Currarino syndrome (CS) is
characterized by sacral agenesis type IV, presacral mass,
and ARM. CS has been associated with mutations in the
MNX1 gene [14–19]. Yet MNX1 mutations account for
only 50% of sporadic and 90% of familial cases [19].
Although private mutations in genes such as VANGL1
[20], HOXD13 [21] and PTEN [22] have been described
in sporadic cases with caudal dysgenesis and/or verte-
brae anomalies, no firm genetic association has been
established.
A CRS-like phenotype can be induced by administra-
tion in animals of retinoic acid (RA), lithium, cadmium,
sulphamide, or organic solvents [23, 24]. Several mu-
tated genes including Cyp26a1, Hoxd13 [25], Wnt-3a
[26], Acd, Ptf1a, and Pcsk5 underlie a CRS-like pheno-
type in mice [10, 27], yet mutations in the human ortho-
logs have never been identified in CRS patients.
Interestingly, the reverse is also true; Mnx1 (formerly
Hxlb9) mutant mice do not present Currarino syndrome
features [28]. These exceptions to human-mouse pheno-
typic correlation suggest differences in genetic etiology
between humans and experimental organisms [10].
In order to search for genetic risk factors for CRS the
exomes of five sporadic CRS cases and their respective
healthy parents were sequenced. Due to the sporadic
nature of the disease we have focused on de novo or
recessive inherited damaging genetic variants. In
addition we also used a SNP chip assay in order to iden-
tify rare and de novo CNVs.
Methods
Subjects
The records of patients treated between 1995–2010 at
the Neurosurgery Department of Giannina (Genoa, Italy)
and at the AbaCid-Genética, Grupo HM Hospitales
(Madrid, Spain) for congenital anomalies of the spine
were reviewed. For all patients, family history, cardiac,
respiratory and endocrine data were collected. This
included family history for diabetes. Neurological, neuro-
physiological (Somatosensory evoked potential, SEP),
radiological, neuroradiologic (MRI), orthopaedic, phys-
ical, urological (urodynamic, cystography) and surgical
assessments were performed for each case. For this pilot
study, we selected four Italian trios (CR5, CR17, CR41,
CR46) as well as one trio from Spain (CURR20). We
only selected cases within this period who had sporadic
lower spine agenesis. Patients were also affected with
additional anomalies of axial skeleton and internal
organs. One child had a mother with diabetes type I.
The local ethical committees approved the study and
written informed consent was obtained from all patients
and parents. Subjects are identified by the trio ID suf-
fixed by either A, B or C indicating father, mother or
child respectively.
Bioinformatics processing
Capture, alignment and base-calling
Whole exome sequencing (WES) was performed at the
Centre of Genomic Sciences of the University of Hong
Kong, Hong Kong. The exomes of all five trios were
sequenced using Illumina HiSeq PE100 and captured
with TruSeq Exome Enrichment kit (FC–121–1024,
Illumina Inc.). The exome sequences were alignment
against Human Genome HG-19 using BWA MEM [29].
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Duplicated reads were flagged with Picard-tools [30].
The GATK tool set was used to realign indels, perform
base recalibration, remove duplicates, perform indel and
SNP calling, and for genotype refinement to improve
accuracy of genotype calls [31]. Data quality for each
variant was scored and a hard threshold used to remove
low data quality variants. We used the GATK recom-
mended criteria for this (see Additional file 1). Related-
ness of our participants was investigated using PLINK
[32]. We then assessed variants for their potential patho-
genicity and frequency, retaining for further analysis
only variants that were rare. We considered a variant to
be rare if its minor allele frequency was ≤1% in each of
several public databases (see Additional file 1). We con-
sidered a variant to be potentially deleterious according
to a score obtained from KGGSeq [33]. KGGSeq’s pre-
diction algorithm makes use of available biological infor-
mation (the mutation’s effect on the gene, i.e. stop gain
or loss, frameshift, splice site, missense), as well as scor-
ing from other publicly available prediction algorithms
(PolyPhen-2, SIFT and others). KGGSeq scores were
only used as an informative instrument, variants were
not removed from the list of possible disease relevant
candidates based on KGGSeq score alone.
De novo, homozygous and compound heterozygous mutations
Single nucleotide variants (SNVs) and small indels
Subsequent analysis of de novo and compound heterozy-
gous, as well as homozygous, mutations was performed
using KGGSeq [33]. For recessive disease models
(homozygous and compound heterozygous) we only
considered variants with a minor allele frequency (MAF)
of less than 1%. We defined a de novo mutation as a first
time genetic alteration of a specific locus in a proband.
Compound heterozygous mutations were defined as the
co-occurrence of two nonsynonymous alleles, one pater-
nal, the other maternal, within a gene. The probability of
de novo mutations in each gene was estimated using the
framework of Samocha et al. [34].
These probabilities were used to guide the assessment
of de novo mutations and not to filter variants. Since a
similar framework was not available for compound het-
erozygous mutations we made use of the only large
control trio dataset publicly available, the Genome of
the Netherlands (GoNL) [35]. The GoNL is a popula-
tion dataset containing 250 unaffected parents-
offspring trios. We estimated the background com-
pound heterozygous mutation rate per gene from the
GoNL dataset. We prioritized compound heterozygous
mutations found in our CRS cases in genes where the
background rate was low. Thus we classed as a candi-
date risk locus any gene for which a recessive or de
novo model could be constructed in any of our trios
using the set of rare potentially deleterious variants we
had identified. Detected de novo, compound heterozy-
gous and homozygous mutations were validated via
Sanger sequencing of trio DNA (i. e. genotypes were
validated in both parents and child).
Analysis of kinship revealed misattributed paternity
within one family (CR46). Hence the family CR46 was
excluded from all family based analyses (de novo,
compound heterozygous and homozygous mutation
analysis).
Copy number variation We investigated copy number
variation (CNV) in the families CR5, CR17 and CR41
with Illumina’s HumanCoreExome-24 beadchip. Quality
control of the assayed genotypes was performed using
GenomeStudio (Illumina Inc.) using the default settings.
CURR20 was also genotyped using CytoScan® HD Array,
but failed initially quality control and was therefore ex-
cluded from the analysis. CNV calling and de novo CNV
detection was performed using PennCNV [36]. We iden-
tified potentially disease associating CNVs as follows.
We retained for further analysis, CNVs which allowed
construction of a recessive disease model for any gene in
any of our trios. We also retained de novo CNVs and
rare CNVs. We deemed a CNV to be rare if it did not
overlap with any CNV detected in the 1000 Genome
Project. De novo CNVs were validated by quantitative
real-time PCR (ABI Prism 7900 Sequence Detection Sys-
tem; Applied Biosystems) using TaqMan® Copy Number
Assay (Catalog #: 4400291). Ensembl’s genome browser
was used to determine genes or regulatory elements
affected by the CNVs [37]. Initially we attempted to call
CNVs from the exome sequencing data on our trios
using three programs (EXCAVATOR [38], CoNIFER
[39], and CONTRA [40]), but found no consistency
between used tools. Similar previous studies have dem-
onstrated limited power for CNV detection from exome
sequencing data tools [41] (Table 1).
Results
After extensive quality control and MAF (MAF ≤ 1%)
filtering we retained 229,849 variants of which 92.4%
were known in dbSNP137. Hence we only retained vari-
ants below the frequency of 1% and those which are
novel. Out of these, 7,442 missense, 184 frameshift, 227
nonframe-shift, 150 splicing, 173 stop-gain and 5 stop-
loss variants in 3,872 different genes were analyzed in
respect to de novo, compound heterozygous and homo-
zygous mutations. Of these variants 236 were either het-
erozygogous or homozygous in all analyzed cases (see
Additional file 2). Out of these, 226 were missense and 10
stop-gain variants distributed across 35 different genes. A
further 65 of these variants were predicted to be damaging
by KGGSeq. We identified two rare mutations in the
known CRS related genes PTEN (rs202004587, missense,
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p.A79T) and VANGL1 (rs74117015, stop-gain, p.Ser338-
Ter) in CR5C inherited from the mother and father
respectively (Table 2). Both were predicted to be
damaging.
De novo variants
In total we identified three de novo mutations, two mis-
sense and one frameshift mutations in three different
genes: MORN1 (p.Gly107Arg), SPTBN5 (p.Glu25Lys),
and ZNF330 (p.Lys3fs) in patients CR41C, CR5C, and
CURR20C respectively (Table 2). MORN1 encodes
MORN (membrane occupation and recognition nexus)
repeats [42]. The exact function of this gene is not
known, however, in Toxoplasma gondii it is known to be
involved in nuclear cell division [43]. Furthermore
MORN repeats are known to be part of a number of
genes, including junctophilins [44] which are involved in
cardiomyopathy [45]. Notably, MORN1 was reported to
be produced by insulin producing cells (IPCs) derived
from pancreatic stem cells [46]. The estimated probabil-
ity for a de novo mutation to occur in MORN1 is 0.8%,
but 59% of all analyzed genes have a lower probability
[34]. Pathogenicity analysis by KGGSeq suggests that the
de novo mutation is damaging.
SPTBN5 (OMIM: 605916) is a beta-spectrin encoding
protein. It plays an important role in linking proteins,
lipids, and cytosolic factors of the cell membrane to the
cytoskeletal filament systems of the cell [47]. SPTBN5 is
expressed in the cerebellum, pancreas, kidney, and blad-
der, as well as in a number of other systems. The gene
has not been associated with any disease or disorder.
The estimated gene-specific probability of de novo muta-
tion is 1.8% and 99% of genes have a lower probability of
having a de novo mutation making this this gene less
likely to be causally related. Further, KGGSeq’s patho-
genic prediction algorithm suggests that this variant is
benign.
ZNF330 (OMIM: 609550) is a zinc finger protein with
no known disease association and is mainly present in
the nucleus during interphase as well as at the centro-
meres during mitosis [48]. Interestingly, this gene is dif-
ferentially expressed in pancreatic Islets of Langerhans
and in peripheral blood mononuclear cells [49]. The es-
timated gene-based de novo mutation probability is
0.6%, relatively low but still within the 28th percentile of
all genes. KGGSeq was unable to predict a pathogenic
score for this variant.
Thus, given the pathogenic nature of the two de novo
variants and their expression pattern in pancreatic cells,
MORN1 and ZNF330 are candidate CRS genes.
We detected one de novo CNV deletion on 3q13.13 in
CR5C (Table 3). The deletion does not seem to encom-
pass any gene or functional element, yet it overlaps with
CNVs previously reported in patients with a similar
phenotype. In particular, a documented de novo deletion
in a Japanese patient with OEIS (omphalocele, exstrophy
of the cloaca, imperforate anus, spinal defects) complex
who also had a sacrum malformation (DECIPHER: 971)
overlaps with the de novo CNV identified in CR5C.
Homozygous and compound heterozygous mutations
In total we identified 8 compound missense heterozy-
gous and one homozygous missense mutations (PDZD2)
which passed the described filtering criteria (detailed in
Table 2). Strikingly, mutations in genes related to dia-
betes were detected in two patients. None of the affected
genes were recurrent. The two genes associated with
diabetes were PDZD2 and CLTCL1 and were found mu-
tated in CR5C and CR17C respectively.
PDZD2 (p.Ser1106Phe) has been shown to be an im-
portant promoter of fetal pancreatic progenitor cell pro-
liferation [50, 51]. Ma et al. [52] showed that expression
of PDZD2 is specific to pancreatic beta cells. Further-
more, higher concentrations of secreted PDZD2 in rat
insulinoma cell lines were correlated with higher rates of
cell proliferation and inhibited transcription of INS, an
insulin promoter.
CLTCL1 (p.Arg1620His, p.Val44Phe) is involved in the
intracellular trafficking of glucose transporter GLUT4.
Intracellular trafficking of the glucose transporter
GLUT4 from storage compartments to the plasma
membrane is triggered in muscle and fat during the
body’s response to insulin [53].
A compound heterozygous mutation in GLTSCR2 (Gli-
oma Tumor Suppressor Candidate Region Gene 2) was
identified in patient CR5C (p.Arg190Trp, p.Thr284Met).
GLTSCR2, is expressed at high levels in pancreas and
heart, is a tumor suppressor gene and a direct regulator of
PTEN. Mutations of PTEN have been previously identified
in a patient affected with VACTERL (Vertebral anomalies,
Anal atresia, Cardiac defects, Tracheoesophageal fistula
and/or Esophageal atresia, Renal & Radial anomalies and
Limb defects) [22] which has commonalities with CRS
[27]. This is especially interesting considering that patient
CR5C is also harbouring a rare inherited mutation in
PTEN itself.
A compound heterozygous mutation (p.Ala1616Thr,
p.Thr3620Leu) in DNAH10, an inner arm dynein heavy
chain, was identified in CR41C. Dynein proteins are im-
plicated in many disorders such as motor neuropathies,
cortical development diseases, as well as congenital mal-
formations such as heterotaxia and situs inversus. More-
over, cytoplasmic Dyneins have been reported to interact
with Kinesin (KIF1A, mutated in patient CR17C) for
interkinetic nuclear migration in neural stem cells [54].
We detected a homozygous CNV deletion encompass-
ing part of chromosome 8p23.2 in patient CR5C
(Table 3). The CNV does not overlap with known genes
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but is contained within a duplication found in a patient
with abnormal sacrum (DECIPHER: 271204). This docu-
mented patient, while also harboring another deletion
(7q34–7q36.3), displayed a great variety of phenotypes
including central hypertonia, hypermetropia, long
thorax, narrow mouth, seizures, strabismus, and deep
set eyes. Additional detected rare CNVs overlapped with
a number of other genes, however, none were known to
be related to CRS (see Additional file 1).
Discussion
Within this pilot study we have identified a number of
novel risk loci potentially connected to CRS. We have
also found a number of mutations for already known
genetic risk factors [10]. Here we highlight these prelim-
inary findings and discuss their relevance for future
studies.
Foremost, all four patients were affected by a homozy-
gous, compound heterozygous mutations or de novo
variant in a diabetes-relevant (CLTCL1 and PDZD2) or
pancreatic expressed (MORN1 and ZNF330) gene. While
these results are not definitive it is in line with the in-
creased CRS risk for children born to diabetic mothers.
In addition, one de novo (chr3q13.13) and one homozy-
gous CNV (chr8p23.2) overlap with CNVs reported in
patients with similar phenotype. Identification of over-
lapping CNVs in patients with similar phenotype is the
central aim of DECIPHER [55]. Since many patients with
rare diseases harbor novel or extremely rare variants, it
is crucial to accumulate evidence across patients in
order to foster understanding of the disease. Further-
more, we identified a heterozygous mutation in
GLTSCR2, a direct regulator of PTEN. PTEN has been
previously associated with CRS-like phenotypes (VAC-
TER) [10]. Interestingly, the same subject (CR5C) has
also an inherited mutation within PTEN and the CRS-
related gene VANGL1. These results further strengthen
the role of PTEN and VANGL1 in CRS. Likewise, the
identification of compound heterozygous mutations in
DNAH10 and KIF1A could suggest an involvement of
ciliary proteins.
There are, a number of limitations to our study. Our
sample size is small, but to be expected given the dis-
ease prevalence and the costs of the genetic assays
used. We were not able to identify recurrent affected
genes across different patients. We did not look for
mutations assuming other than recessive inheritance
because the yield of true to false positives would be
poor. Many types of genetic variation were not
assayed, for instance we only assayed exomic SNVs.
Lastly, models involving environment, such as gene-
environment interactions within the utero, could not
be investigated.
The diversity of identified potential disease mecha-
nisms matches that of previous studies [10, 56–58] and
also reflects the phenotypic diversity associated with
CRS [56]. We previously showed that if a disorder is
genetically complex, one should expect large genetic het-
erogeneity across patients [59]. Thus the number of can-
didate genes identified is not surprising and is similar to
that reported for other complex rare genetic disorders
[60]. While the presence of several possible disease
mechanisms does not necessary suggest a multigenic
model, the large number of candidate genes identified
within this study, as well as those reported by others
[23, 27, 61–64] suggests that CRS might be caused by
a multitude of private genetic risk factors. This makes
identification of a common underlying genetic archi-
tecture challenging. Furthermore, differences in the
genetic etiology between humans and experimental
organisms makes it difficult to investigate the exact
causal mechanism. Many aspects of the disease are
still poorly characterized, for example, disease preva-
lence. While some studies have estimated that 1 in
7,700 children might be affected [1], others suggest it
might be as rare as 1 in 100,000 births [2]. This fur-
ther complicates estimation of the number of disease
causing mechanisms [59].
Table 3 De novo and homozygous CNVs
Patients Chromosome Start Position End Position Length Type Genes or regulatory
elements
Patients with related symptoms
listed in DECIPHER (type of CNV,
patient phenotype)
CR5C
3q13.13 109489534 109510473 20939 De novo/deletion – 971, deletion; abnormality of the
sacrum, Abnormality of the small
intestine, Anal atresia, Cloacal
exstrophy, Omphalocele, Spina
bifida occulta.
8p23.2 5599399 5605087 5688 homozygous/deletion – 271204, duplication; Abnormality
of the sacrum, Central hypotonia,
Deeply set eye, Hypermetropia,
Long thorax, Narrow mouth,
Nasogastric tube feeding in
infancy, Seizures, Strabismus.
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Conclusions
Despite the complexity of the phenotype, we were able
to identify common genetic characteristics across
patients, potentially causally related to the known risk
factors and supposed disease etiology. Our data,
although limited to a small group of patients, support a
multigenic model for CRS. Future studies should con-
sider larger accumulated samples across multiple centers
in order to identify common genetic characteristics via
whole genome or whole exome sequencing.
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